What The Cooper Companies, Inc. told the SEC could break it.

CooperSurgical's fertility labs (US, UK, Japan) require CLIA certificates and HFEA/state/foreign licenses; sanctions, non-renewal or loss of accreditation could materially harm its diagnostic-testing business, on top of FDA/foreign device-approval requirements.

“Any sanction imposed under CLIA, its implementing regulations, or state or foreign laws or regulations governing licensure, or our failure to renew a CLIA certificate, or a state or foreign license or accreditation, could have a material and adverse effect on our diagnostic testing business, operating results and financial condition.”

Cooper's international operations face tariffs, exchange controls and trade restrictions — including Chinese tariffs on certain US goods of uncertain scope/duration — that could affect its emerging-market growth and earnings.

“foreign earnings being subject to withholding requirements or the imposition of tariffs, exchange controls or other restrictions, including the tariffs enacted by the Chinese government on certain U.S. goods, the scope and duration of which remain uncertain;”

Primary material for Cooper's silicone hydrogel contact lenses (MyDay, Biofinity, Avaira, clariti) is supplied by few or sole suppliers, and certain medical-device/IVF components are sole-sourced; a key/sole supplier failure could materially disrupt lens supply.

“For example, among other situations, some of the primary material used to make our silicone hydrogel contact lens products, including MyDay, Biofinity, Avaira and clariti, are supplied by few or sole suppliers, and the failure of a key or sole supplier to timely supply sufficient items and materials necessary for the manufacture of our silicone hydrogel contact lenses could in turn disrupt our supply of those lenses to the market, which would have a material adverse effect on our business.”